Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...

The research team at the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences confirmed the ...

A new study has identified the protein hnRNP A1 as a key player in the production and maintenance of myelin, the fatty sheath ...

Study uncovers how the protein hnRNP A1 may impact myelin stability, offering new clues in schizophrenia development.

The development of drugs to treat major diseases of the central nervous system relies in part on the development of novel strategies to cross the blood brain barrier. Michel Khrestchatisky and ...

The virus that causes shingles is just one of a number of pathogens that may be linked to brain conditions. Here are some of ...

Researchers in optics and brain and cognitive science are investigating whether neurons can transmit light in a manner ...

Research published in the Journal of Neurochemistry has detailed the role of a protein, hnRNP A1, in the formation and ...

Northeastern University scientists have discovered that a protein in the human brain could potentially be used to grow new ...

Mr Radie brings more than three decades of experience working in both public and private pharmaceutical and biotech companies. Having been involved in the launch of blockbuster antidepressant and ...

a precision-neuroscience company focused on the development of innovative treatments for serious central nervous system disorders (CNS), today announced two key leadership appointments.

Neurodegenerative diseases are a heterogeneous group of disorders that are characterized by the progressive degeneration of the structure and function of the central nervous system or peripheral ...